Outlook Therapeutics, Inc.
OTLK
$0.64
$0.000.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.16M | 333.10K | 205.70K | 1.41M | 1.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.16M | 333.10K | 205.70K | 1.41M | 1.51M |
| Cost of Revenue | 1.11M | 1.54M | 1.39M | 1.36M | 439.80K |
| Gross Profit | -2.28M | -1.20M | -1.18M | 57.20K | 1.07M |
| SG&A Expenses | 36.00M | 38.12M | 36.60M | 39.94M | 39.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.47M | 60.91M | 59.14M | 68.48M | 74.13M |
| Operating Income | -55.64M | -60.57M | -58.94M | -67.06M | -72.62M |
| Income Before Tax | -62.68M | -62.51M | -104.41M | -63.98M | -43.44M |
| Income Tax Expenses | -1.55M | -1.55M | -1.55M | -1.55M | 2.80K |
| Earnings from Continuing Operations | -61.12 | -60.96 | -102.86 | -62.42 | -43.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.12M | -60.96M | -102.86M | -62.42M | -43.44M |
| EBIT | -55.64M | -60.57M | -58.94M | -67.06M | -72.62M |
| EBITDA | -55.53M | -60.45M | -58.82M | -66.94M | -72.51M |
| EPS Basic | -0.87 | -1.26 | -2.71 | -1.61 | -1.09 |
| Normalized Basic EPS | -0.50 | -0.72 | -1.56 | -0.91 | -0.55 |
| EPS Diluted | -0.87 | -1.27 | -2.71 | -1.61 | -1.09 |
| Normalized Diluted EPS | -0.50 | -0.72 | -1.56 | -0.91 | -0.55 |
| Average Basic Shares Outstanding | 325.98M | 226.19M | 175.23M | 139.26M | 115.79M |
| Average Diluted Shares Outstanding | 325.98M | 226.19M | 175.23M | 139.26M | 115.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |